Effect of statins on serum prostate-specific antigen levels

Objectives: The use of statins, which are cholesterol-lowering drugs, has increased significantly during the last decade. In this study, we investigate the effect of statins on serum prostate-specific antigen (PSA) levels in men participating in a prostate cancer screening event. Methods: A cohort of 4903 men who participated in Prostate Cancer Awareness Week in the years 2007 or 2008 were enrolled in this study from multiple clinical institutions. Within this cohort 1379 men (28.2%) were on a statin medication. Serum PSA, total testosterone, and total cholesterol were compared between the cohort of men using statins and the cohort of men who did not indicate current statin use. In multivariate regression analysis we controlled for age, body mass index (BMI), and race. Results: The mean age of the population was 60.7 years. Serum testosterone levels in patients on statin medication were significantly lower than in patients not on statins (P < .001). Mean total cholesterol levels were similar between the 2 groups (P = .229). Mean serum PSA level was 1.56 ng/mL in patients on statin medication and 1.48 ng/mL in patients not on statin (P = .120). After adjusting for significant covariates (age, BMI, and race), statin use was shown to have a significant association with lower mean PSA (P = .008) and lower mean testosterone (P < .001) and similar total cholesterol (P = .083). Conclusions: Although use of statins may lower serum PSA levels, its clinical impact is limited. It may not be necessary to determine a different PSA cutoff level for patients on statin medication. © 2010 Elsevier Inc. All Rights Reserved.

Yazar Akduman B.
Tandberg D.J.
O'Donnell C.I.
Hughes A.
Moyad M.A.
Crawford E.D.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/5383
Tek Biçim Adres 10.1016/j.urology.2010.03.044
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı Urology
Dergi Cilt Bilgisi 76
Dergi Sayısı 5
Sayfalar 1048 - 1051
Yayın Yılı 2010
Eser Adı
[dc.title]
Effect of statins on serum prostate-specific antigen levels
Yazar
[dc.contributor.author]
Akduman B.
Yazar
[dc.contributor.author]
Tandberg D.J.
Yazar
[dc.contributor.author]
O'Donnell C.I.
Yazar
[dc.contributor.author]
Hughes A.
Yazar
[dc.contributor.author]
Moyad M.A.
Yazar
[dc.contributor.author]
Crawford E.D.
Yayın Yılı
[dc.date.issued]
2010
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Objectives: The use of statins, which are cholesterol-lowering drugs, has increased significantly during the last decade. In this study, we investigate the effect of statins on serum prostate-specific antigen (PSA) levels in men participating in a prostate cancer screening event. Methods: A cohort of 4903 men who participated in Prostate Cancer Awareness Week in the years 2007 or 2008 were enrolled in this study from multiple clinical institutions. Within this cohort 1379 men (28.2%) were on a statin medication. Serum PSA, total testosterone, and total cholesterol were compared between the cohort of men using statins and the cohort of men who did not indicate current statin use. In multivariate regression analysis we controlled for age, body mass index (BMI), and race. Results: The mean age of the population was 60.7 years. Serum testosterone levels in patients on statin medication were significantly lower than in patients not on statins (P < .001). Mean total cholesterol levels were similar between the 2 groups (P = .229). Mean serum PSA level was 1.56 ng/mL in patients on statin medication and 1.48 ng/mL in patients not on statin (P = .120). After adjusting for significant covariates (age, BMI, and race), statin use was shown to have a significant association with lower mean PSA (P = .008) and lower mean testosterone (P < .001) and similar total cholesterol (P = .083). Conclusions: Although use of statins may lower serum PSA levels, its clinical impact is limited. It may not be necessary to determine a different PSA cutoff level for patients on statin medication. © 2010 Elsevier Inc. All Rights Reserved.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0090-4295
İlk Sayfa Sayısı
[dc.identifier.startpage]
1048
Son Sayfa Sayısı
[dc.identifier.endpage]
1051
Dergi Adı
[dc.relation.journal]
Urology
Dergi Sayısı
[dc.identifier.issue]
5
Dergi Cilt Bilgisi
[dc.identifier.volume]
76
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1016/j.urology.2010.03.044
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/5383
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
16
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
08 Nisan 2024 02:44
Google Kontrol
Tıklayınız
statin statins patients levels medication cohort cholesterol testosterone clinical significant between similar significantly cutoff different groups association necessary Elsevier Rights Reserved determine adjusting covariates Conclusions Although impact limited Objectives population antigen Prostate participated Methods screening
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms